Bleb Function and Morphology With Intratendon Injection of MMC Compared With Standard Method

NCT ID: NCT02385370

Last Updated: 2015-03-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with advanced glaucoma that are candidates for trabeculectomy will be included.

Thorough ophthalmic examination including best corrected visual acuity, slit lamp examination, intraocular pressure (IOP) measurement, gonioscopy, funduscopy and specularly microscopy will be performed for all participants. Patients will be assigned randomly to 2 groups. In one group they will undergo fornix based trabeculectomy with conventional MMC 0.02% soaked sponges application. In the other group 0.1 cc of 0.01 MMC will be injected into the tenon at the beginning of the surgery. The rest of the operation is the same for both groups as standard trabeculectomy. Ophthalmic examination including IOP measurement will be performed at one, 3 and 6th month post surgery. Specular microscopy will be requested at final follow up visit. Bleb morphology will be scored according to Indian grading system at 3rd and 6th months post surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

using standard method of applying MMC

applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes

Group Type ACTIVE_COMPARATOR

MMC

Intervention Type DRUG

using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes

intratendon injection of MMC

intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure

Group Type ACTIVE_COMPARATOR

MMC

Intervention Type DRUG

0.1 cc of 0.01% MMC is injected into the tenon.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MMC

using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes

Intervention Type DRUG

MMC

0.1 cc of 0.01% MMC is injected into the tenon.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced uncontrolled glaucoma patients.

Exclusion Criteria

* History of any kind of intraocular surgery.
* Monocular patients.
* Unwillingness to participate in the study
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shahid Beheshti University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zahra Rabbani Khah

Shahid Beheshti Medical University

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tehran, , Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

mohammad pakravan

Role: CONTACT

009822591616

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

mohammad pakravan

Role: primary

009822591616

References

Explore related publications, articles, or registry entries linked to this study.

Pakravan M, Esfandiari H, Yazdani S, Douzandeh A, Amouhashemi N, Yaseri M, Pakravan P. Mitomycin C-augmented trabeculectomy: subtenon injection versus soaked sponges: a randomised clinical trial. Br J Ophthalmol. 2017 Sep;101(9):1275-1280. doi: 10.1136/bjophthalmol-2016-309671. Epub 2017 Jan 18.

Reference Type DERIVED
PMID: 28100482 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

92181

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Primary Tube Versus Trabeculectomy Study
NCT00666237 COMPLETED PHASE4
Retinal Blood Flow and Autoregulation
NCT05344274 RECRUITING PHASE4